Recruiting NCT03966443
Fluciclovine PET/CT in Multiple Myeloma Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Myeloma, Multiple, PET-CT. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Norway
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Overview
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
Primary outcome measures
- Comparing of image findings at PET [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Multiple myeloma patients suitable for ASCT treatment
Exclusion criteria
- Patients with contraindications to ASCT treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Norway · 1 center
- Oslo University Hosptal — Oslo
Identifiers
NCT: NCT03966443 · 2018/2212/REK